Drug details

Zypitamag (pitavastatin tablets for oral use)

type of Lipid-Lowering Agents, Statins, HMG-CoA Reductase Inhibitors

Zypitamag (pitavastatin) tablets are an HMG-CoA reductase inhibitor indicated for patients with primary hyperlipidemia or mixed dyslipidemia as an adjunctive therapy to diet to reduce elevated total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo B), triglycerides (TG), and to increase high-density lipoprotein cholesterol (HDL-C).

This drug may have the following side effects:

• hives,
• difficulty breathing,
• swelling of your face, lips, tongue, or throat,
• loss of appetite,
• dark urine,
• clay-colored stools, and
• yellowing of the skin or eyes (jaundice)
• vomiting,
• confusion,
• tiredness,
• swelling,
• stomach pain (upper right side),
• rapid weight gain,
• little or no urinating,
• pain in your side or lower back,
• muscle weakness in your hips, shoulders, neck, and back,
• trouble lifting your arms,
• trouble climbing or standing,

The following drugs are related to Zypitamag, either as a replacement or used together:

• Atorvaliq (atorvastatin)
• Evkeeza (evinacumab-dgn for injection)
• Ezallor (rosuvastatin calcium tablets)